Evidence map›Paper›PMID 39729204›Full record

SynthesisNaunyn-Schmiedeberg's archives of pharmacology2025

The efficacy and safety of Empagliflozin on outcomes of patients with myocardial infarction undergoing primary PCI: a systematic review and meta-analysis.

Azin Alizadehasl, Hoda Hakimian, Leyla Abdolkarimi, Yasamin Afsari Zonooz, Ehsan Amini-Salehi, Seyedeh Fatemeh Hosseini Jebelli, Azam Yalameh Aliabadi

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Azin AlizadehaslCardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Science, Tehran, Iran.
Hoda HakimianCardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Science, Tehran, Iran.
Leyla AbdolkarimiRajaie Cardiovascular Medical and Research Center, Iran University of Medical Science, Tehran, Iran.
Yasamin Afsari ZonoozCardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Science, Tehran, Iran.
Ehsan Amini-SalehiGuilan University of Medical Science, Rasht, Iran.
Seyedeh Fatemeh Hosseini Jebelli *Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Science, Tehran, Iran. sfhoseini.mail@gmail.com.
Azam Yalameh Aliabadi *Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Science, Tehran, Iran. azamyalameh67@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has garnered significant interest due to its potential cardiovascular benefits, particularly in patients experiencing acute myocardial infarction (AMI) who are undergoing primary percutaneous coronary intervention (PCI). This systematic review aims to evaluate the effectiveness of Empagliflozin in improving clinical outcomes in this patient population. A systematic review of randomized controlled trials (RCTs) was conducted to assess the effects of Empagliflozin on clinical outcomes in patients with AMI undergoing primary PCI. Electronic databases, including PubMed, Scopus, Web of Science, Cochrane, and the Scientific Information Database, were searched up to July 31, 2024. The risk of bias in the included studies was evaluated using the Cochrane Collaboration criteria. Data analysis was performed using Comprehensive Meta-Analysis software version 3, with outcomes expressed as risk ratios (RR) and 95% confidence intervals (CI). Seven studies were included in the meta-analysis. The results demonstrated that Empagliflozin significantly reduced the risk of heart failure hospitalization compared to placebo, with a risk ratio of 0.48 (95% CI: 0.23-0.99; P = 0.049), indicating a 52% reduction in hospitalization risk. However, secondary outcomes showed that Empagliflozin was associated with a reduction in cardiovascular mortality (RR = 0.45; 95% CI: 0.06-3.02; P = 0.415) and the need for coronary revascularization (RR = 0.75; 95% CI: 0.15-3.59; P = 0.717), although these results did not achieve statistical significance. Empagliflozin is associated with a significant reduction in heart failure hospitalizations among patients with AMI undergoing primary PCI, while its effects on cardiovascular mortality and the necessity for coronary revascularization were not statistically significant. Despite these secondary outcomes, the favorable safety profile of Empagliflozin supports its use as a treatment option for high-risk patients following acute coronary events. Further research is warranted to investigate the long-term impact of Empagliflozin on cardiovascular outcomes in this population.

Indexed as

Benzhydryl CompoundsGlucosidesMyocardial InfarctionPercutaneous Coronary InterventionSodium-Glucose Transporter 2 InhibitorsHumansRandomized Controlled Trials as TopicTreatment OutcomeBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsCardiovascular mortalityCoronary revascularizationEmpagliflozinHeart failure hospitalizationMyocardial infarctionPrimary PCI

Identifiers

PMID39729204

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.